Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial - 29/11/17
, Hervé Puy b, c, d, e, Grégoire Mercier f, Sylvain Lehmann gthe Hepcidane study group
, Alain Mercat i , Thomas Gaillard i , Soizic Gergaud i , Sigismond Lasocki i , Cyrille Sargentini i , Claire Geneve j , Philippe Montravers j , Thibault Lefebvre k , Herve Puy k , Grégoire Mercier l , Nicolas Nagot m , Constance Delaby m , Christophe Hirtz m , Sylvain Lehmann m , Jérôme Vialaret m , Gerald Chanques n , Samir Jaber n , Karim Asehnoune o , Antoine Roquilly o , Claire Dahyot-Fizelier p , Olivier Mimoz p , Sonia Isslame q , Philippe Seguin q , Mathilde Barbaz r , Martine Ferrandiere r Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
Iron deficiency (ID) is frequent but difficult to diagnose in critically ill patients. ID may be responsible for prolonged post-ICU hospital stays, since it results in fatigue, muscle weakness and anaemia. Hepcidin, the key iron metabolism hormone, may be a good marker of ID in these patients. The aim of this study is to determine whether using mass spectrometry hepcidin determination to diagnose (and treat) ID after prolonged ICU stays may reduce patients’ subsequent hospital stays and costs in comparison with conventional (ferritin) methods.
Methods |
This is a randomised, controlled, single-blinded, multicentre medico-economic study. Hepcidin quantification will be performed in anaemic (WHO criteria) critically ill adults about to be discharged, after a stay ≥5days. In the intervention arm (hepcidin) results will be given to the ICU-physicians, and not in the control arm. ID Treatment will be recommended in intervention arm: IV iron when hepcidin is <20μg/L; IV iron+erythropoietin when hepcidin is between 20–41μg/L; in the control arm: IV iron when ferritin <300μg/L and Transferrin saturation <20%. The primary endpoint will be the number of days spent in hospital 90 days after ICU discharge and the direct hospital costs. Secondary endpoints will be anaemia and iron deficiency on D15, fatigue and the proportion of patients alive and at home on D30 and D90.
Discussion |
The results of this study will show whether diagnosing iron deficiency using MS hepcidin determination methods is liable to reduce patients’ post-ICU hospital stay and costs, as well as their anaemia and fatigue.
Le texte complet de cet article est disponible en PDF.Keywords : Anaemia, Critical care, Iron deficiency, Hepcidin, Length of stay, Medical costs
Plan
Vol 36 - N° 6
P. 391-396 - décembre 2017 Retour au numéro
Article précédent
- The clinical impact and prevalence of emergency point-of-care ultrasound: A prospective multicenter study
- Xavier Bobbia, Laurent Zieleskiewicz, Christophe Pradeilles, Chloé Hudson, Laurent Muller, Pierre Géraud Claret, Marc Leone, Jean-Emmanuel de La Coussaye, Winfocus France Group
- Peripheral venous catheter insertion simulation training: A randomized controlled trial comparing performance after instructor-led teaching versus peer-assisted learning
- Sophie Pelloux, Arnaud Grégoire, Patrice Kirmizigul, Sandrine Maillot, Bernard Bui-Xuan, Guy Llorca, Sylvain Boet, Jean-Jacques Lehot, Thomas Rimmelé
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?